BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27870570)

  • 21. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma.
    Xia R; Zhou R; Tian Z; Zhang C; Wang L; Hu Y; Han J; Li J
    Arch Pathol Lab Med; 2013 Dec; 137(12):1761-9. PubMed ID: 24283856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    Couvreur K; Celine J; Marlies B; Randal D; Philippe D; Frederic D; Sylvie R
    Acta Clin Belg; 2020 Oct; 75(5):362-369. PubMed ID: 31232197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland.
    Sung JY; Ahn HK; Kwon JE; Jeong H; Baek CH; Son YI; Ahn YC; Park K; Ahn MJ; Ko YH
    J Oral Pathol Med; 2012 May; 41(5):415-23. PubMed ID: 22077630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
    Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
    Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
    Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
    J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-NOTCH1 therapy with OMP-52 M51 inhibits salivary adenoid cystic carcinoma by depressing epithelial-mesenchymal transition (EMT) process and inducing ferroptosis.
    Li R; Hu Z; Qiao Q; Zhou D; Sun M
    Toxicol Appl Pharmacol; 2024 Mar; 484():116825. PubMed ID: 38253083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early stage minor salivary gland adenoid cystic carcinoma has favourable prognosis.
    Hämetoja H; Hirvonen K; Hagström J; Leivo I; Saarilahti K; Apajalahti S; Haglund C; Mäkitie A; Bäck L
    Virchows Arch; 2017 Dec; 471(6):785-792. PubMed ID: 28600602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
    Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type.
    Bell D; Bell AH; Bondaruk J; Hanna EY; Weber RS
    Cancer; 2016 May; 122(10):1513-22. PubMed ID: 26953815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
    Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
    Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of gefitinib in patients with advanced salivary gland cancers.
    Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
    Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands.
    Hirvonen K; Bäck L; Haglund C; Leivo I; Jouhi L; Mäkitie AA; Hagström J
    Tumour Biol; 2016 Aug; 37(8):10959-64. PubMed ID: 26888781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands.
    Bazarsad S; Kim JY; Zhang X; Kim KY; Lee DY; Ryu MH; Kim J
    Yonsei Med J; 2018 Aug; 59(6):717-726. PubMed ID: 29978608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
    Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
    Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.
    Fujii K; Murase T; Beppu S; Saida K; Takino H; Masaki A; Ijichi K; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Inagaki H
    Histopathology; 2017 Nov; 71(5):823-834. PubMed ID: 28594149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
    Panaccione A; Chang MT; Carbone BE; Guo Y; Moskaluk CA; Virk RK; Chiriboga L; Prasad ML; Judson B; Mehra S; Yarbrough WG; Ivanov SV
    Clin Cancer Res; 2016 Apr; 22(8):2083-95. PubMed ID: 27084744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
    Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thioredoxin 1 mediates TGF-β-induced epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.
    Jiang Y; Feng X; Zheng L; Li SL; Ge XY; Zhang JG
    Oncotarget; 2015 Sep; 6(28):25506-19. PubMed ID: 26325518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma.
    Zhang Y; Liu X; Zhu L; Zhou Z; Cui Y; Zhou CX; Li TJ
    Oral Dis; 2024 Apr; 30(3):1220-1233. PubMed ID: 36951790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.